ly2409881

LY2409881 is a potent and selective small molecule inhibitor of IκB kinase beta (IKKβ, also known as IKK2), with an IC50 of 30 nM and greater than 10-fold selectivity over IKK1 and other common kinases[1][9]. It inhibits the NF-κB signaling pathway by blocking IKK2 activity, leading to concentration- and time-dependent growth inhibition and apoptosis in various cancer cell lines, particularly those with constitutively activated NF-κB, such as certain lymphomas[1][3][7]. In preclinical models, LY2409881 demonstrated significant antitumor activity, especially when combined with histone deacetylase inhibitors, suggesting potential as part of combination regimens for hematologic malignancies[3][10]. LY2409881 was originally developed by Eli Lilly[5].

Other names

LY 2409881LY2409881LY-2409881LY-2409881 trihydrochlorideLY2409881 trihydrochlorideLY 2409881 trihydrochloride2-[5-chloro-2-[3-(4-methylpiperazin-1-yl)propylamino]pyrimidin-4-yl]-N-cyclopropyl-1-benzothiophene-4-carboxamide